Nuvation Bio (NUVB) Stock
Clinical stage biotech developing targeted cancer treatments. Here's the price, business snapshot, and what's worth knowing about Nuvation Bio in July 2026.
Nuvation Bio Inc (NUVB) is a clinical‑stage biopharmaceutical company focused on developing targeted oncology treatments. With a market capitalisation of about $1.45 billion, the company’s value is driven by progress across its pipeline, clinical trial readouts and regulatory milestones rather than steady revenue. Investors should note that clinical‑stage biotechs often face binary outcomes — trial successes can meaningfully re‑rate the stock, while setbacks or regulatory delays can weigh heavily on the share price. Key considerations include cash runway, partnership or licensing deals, trial enrolment and data timelines. The stock can be volatile and suited to investors who accept higher risk for potential long‑term upside. This summary is educational and not personalised investment advice; it does not recommend buying or selling. Always assess suitability for your financial situation and consider seeking independent financial advice before making investment decisions.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Nuvation Bio's stock with a target price of $8.2, indicating potential growth.
Financial Health
NuVation Bio Inc is showing strong revenue and cash flow, with impressive profit margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring NUVB
Injectable Drug Innovation Opportunities 2025
The FDA's approval of an at-home injectable version of Eisai and Biogen's Alzheimer's drug, Leqembi, simplifies treatment for patients and caregivers. This development highlights a growing trend toward patient-centric care, creating investment opportunities in companies that specialize in innovative drug delivery systems and at-home therapeutic technologies.
Published: 31 August 2025
Explore BasketTargeting Superbugs: The Next Wave Of Antibiotics
GSK's new antibiotic for gonorrhea has received priority review from the FDA, underscoring the urgent need for new antimicrobial treatments. This event signals a potential resurgence in the market for companies developing novel antibiotics to address drug-resistant infections.
Published: 11 August 2025
Explore BasketLottery Tickets
These visionary companies are betting it all on game-changing innovations that could revolutionize entire industries. Hand-selected by our analysts, each represents a high-risk, high-reward opportunity with potential for explosive growth if their breakthrough technologies succeed.
Published: 17 June 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical Milestones Ahead
Upcoming trial readouts and regulatory steps can act as catalysts for valuation, though outcomes are uncertain and can drive volatility.
R&D‑Driven Progress
The company’s value depends on scientific progress and development execution; this can offer upside but also increases cash‑burn and execution risk.
Partnership Potential
Licensing or collaborations can provide funding and validation, but depend on successful data and mutual strategic fit; terms and timing vary.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
